Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Inside Gilead Sciences, colleagues often describe Varun Sharma as the strategist who can map a launch plan end to end, and ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences ( ($GILD) ) just unveiled an announcement. On August 10, 2025, Gilead Sciences announced the appointment of Erin Burkhart as ...

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...